Phase 2 N=36 In Vivo Assessment of Silver Biomaterial Nano-Toxicity
Healthy
Primary: Change in Sodium Blood Levels — -0.1; 0.2 mmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=27 Experimental Human Infection With Neisseria Gonorrhoeae
Gonococcal Infection
Primary: The Competitive Index of the Mutant Compared to Wild Type Proportion of Organisms With the Predicted Competitive Advantage Recovered From Urine and/or Urethral Swab…
N/A N=45 Clinical Experiment of Helicobacter Pylori Transmission
Infection · Achlorhydria
Primary: Development of Diarrhea — 5; 6 participants
Phase 2 N=48 Influenza A 2009 H1N1 Challenge Study in Healthy Adults
Influenza
Primary: Percent MMID — 0; 0; 20; 47 percentage of participants
N/A N=118 Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
Allergic Sensitization
Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants
Phase 2 N=72 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Ebola Virus Infection
Primary: Mortality — 13; 8 Participants
N/A N=12 Project 3 Example: Human-AI Collaboration Tester (HAICT) Exp. 7
Decision Making · Computer Aided Diagnosis
Primary: D' — 1.69; 1.93; 1.86; 1.92 d'
Phase 1 N=19 Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Healthy Adult Immune Responses to Vaccine
Primary: Number of Subjects Experiencing Infusion Reaction During Product Administration — 0; 0; 0; 3 Participants
Phase 2 N=128 Analyzing Female Trauma Exposed Responses to a Medication
Stress Disorders, Post-traumatic
Primary: Efficacy, Measured by Change in the Clinician-Administered PTSD Scale (CAPS) Score — -26.02; -27.33 score on a scale
N/A N=25 Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens
Respiratory Tract Infections
Primary: RD19 Acceptability — 1; 0; 1; 9 Participants
Phase 1 N=16 Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)
Gonococcal Infection
Primary: The Proportion of Participants That Become Infected With Individual N. Gonorrhoeae Strains in Non-competitive Infections — 0.80; 1.00 proportion of participants — p=1.000
Phase 1 N=20 Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)
Dengue
Primary: Number of Participants With Solicited Injection Site Adverse Events — 1; 0 Participants
N/A N=32 Wireless Disposable SpO2 Sensor Hypoxia Testing
SpO2 · Peripheral Oxygen Saturation Measurement
Primary: Collection of Subject SpO2 Percentage Sensor Data With Transfer Standard Measurements for Validation — 31 data sets
N/A N=74 Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.
Hiv · HIV Testing
Primary: HIV Testing Related Knowledge and Practice — 17.17; 17.22; 19.44; 17.36 score on a scale — p=<0.001
N/A N=11 Teleoperation Experimental Comparison With Able-bodied Subjects
Amputation; Traumatic, Arm, Upper
Primary: Transfer Success Rate in a Fragile Box and Blocks Task — 67.50; 72.75; 93.46; 95.06 percentage of attempted transfers — p=<0.001
Phase 3 N=200 Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Anthrax
Primary: Percentage of Subjects Achieving a TNA Response of a Predefined Threshold Value at Day 63 (5 Weeks Following the Third Vaccination on Day 28). — 71.2; 68.5; 73.9; 76.7…
Phase 2 N=12 In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm
Healthy
Primary: Change Sodium Blood Levels — 141.8; 141.2 mmol/L
Phase 3 N=680 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
Ebola Virus
Primary: Mortality — 93; 61; 52; 84 deaths
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=26 VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Phase 1 N=50 Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Influenza
Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each HA-F A/Sing Product Administration — 4; 3; 7; 9 Participants
N/A N=20 Feasibility of BabyGentleStick- Adult Pilot Study
Lack of Adverse Events · Reduced Pain Response
Primary: Number of Adverse Events — 0; 1 events
Phase 1 N=24 Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10
Healthy
Primary: the Cases of Adverse Events With Participant Injection of ESAT6-CFP10 — 3; 1; 0; 0 cases
Phase 3 N=24,111 Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay
Healthy Donors · HIV Positive
Primary: PRISM HIV O Plus Test Data for Specificity — 10; 15589 participants
Phase 1 N=76 H1N1v Virus Challenge Study in Healthy Subjects
Influenza
Primary: Percentage of Healthy Participants Reporting Mild-to-Moderate Influenza Disease (MMID) by Baseline A/Bethesda/MM2/H1N1 Hemagglutination Inhibition (HAI) Antibody…
N/A N=33 Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain
Influenza A H3N2
Primary: Occurrence of Adverse Events Related to the Viral Challenge — 0; 0; 1; 6 Occurrence of adverse events
Phase 2 N=260 Leprosy Skin Test Antigens Trial
Leprosy
Primary: Number of Participants With Reactions to the Antigen Mycobacterium (M.) Leprae Soluble Antigen (MLSA)-Lipoarabinomannan (LAM) at Doses of 0.1 Microgram — 0; 3; 1; 5…
N/A N=159 Testing and Calibration of Non-Invasive Optical Imaging Technology for Functional Brain Imaging
Cognition
Primary: Relationship Between Prefrontal Cortex Activation and Respiratory Sinus Arrhythmia — -0.064; 0.00375 Micro mol per second — p=0.008
N/A N=31 A Multiple-Dose Research Study on Safety Evaluation of the GD Antrodia Camphorata in 30 Healthy Adult Subjects
Healthy
Primary: Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) — 21.48 U/L
N/A N=20,460 Covid-19 Messaging to Underserved Communities - 2nd Experiment
Covid19
Primary: Incidence Rate for Knowledge Gaps: Control vs. Any Intervention — 0.214; 0.241 proportion of knowledge gaps